On December 29, the selection of "Outstanding Innovation and Entrepreneurship Talents in Zhangjiang National Independent Innovation Demonstration Zone" was held for the first time by the Shanghai Promotion of Science and Technology Innovation Center Construction Office and the Shanghai Municipal Human Resources and Social Security Bureau, and the results were officially announced.

Dr. Wan Yakun of Luoqi Biology was selected successfully!

This talent selection is the first time in the ten years since the construction of "Dazhangjiang", which is known as "first try". The selection process took several months. After several rounds of defense selection, 100 strategic scientists, leading entrepreneurs and young scientific and technological talents who made outstanding contributions to the construction of Zhangjiang National Independent Innovation Demonstration Zone were commended.

As the founder of Rocky Biology, Dr. Wan Yakun has been deeply engaged in the field of nanoantibody for more than ten years and has extremely rich experience in nanoantibody projects. Since the founding of Loqi Biology in 2017, Dr. Wan Yakun has led the team to achieve breakthrough innovative scientific research results and significant industrialization results, and successfully pushed the world's first inhaled nano-antibody asthma treatment drug LQ036 into phase I clinical. In the future, Dr. Wan Yakun will give full play to the leading role of demonstration, lead the team to continue exploring research and development and achievement transformation, and continue to make new and greater contributions to innovation and entrepreneurship.

About novamab

     Luoqi Biology is a high-tech enterprise dedicated to the research and development of innovative nano antibody drugs. The company was founded on October 16, 2017 and is located in Shanghai International Medical Park. It has a research and development and production base of more than 2600 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nanoantibodies, each of which has unique industry advantages. Based on the innovative technology platform, Rocky Biology has a diversified R&D pipeline composed of more than 50 nanoantibody drug projects, covering hot targets such as asthma, fibrosis, ophthalmology and cancer.